What changed
What changedThe Cigna Group reported third-quarter 2026 results, with quarterly revenue of $73.7 billion. This is a 5.6% increase from the same period last year, while the company's net income fell 22.8% to $1.4 billion.

What changedOn November 5, 2026, The Cigna Group reported third-quarter 2026 financial results, with total revenue up 6% to $73.7 billion. Adjusted income from operations was $2.1 billion, or $7.98 per share, a key profitability metric for shareholders.

What changedOn September 30, 2026, Cigna Group held Investor Day, presenting a strategy to increase affordability and personalization of medical services, and on October 9, director Donna F. Zarcone announced her departure from the board, effective December 31, 2026.

Company history
October 2026
Cigna Group: 12 recorded developments from 3 official sources in 2026-10.
- 2026-09-30: On September 30, 2026, The Cigna Group issued a press release noting that the Company will host its Investor Day, both in person and virtually, beginning at approximately 8:30 a.m. Eastern Time. Source
- 2026-09-30: Deliver core growth: Build on the strong foundation of a deliberately shaped portfolio — including Cigna Healthcare and Evernorth’s Specialty & Care Services and Pharmacy Benefit Services — to drive growth Source
- 2026-09-30: The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Source
- 2026-09-30: The Investor Day presentations are expected to begin on September 30, 2026 at approximately 8:30 a.m. Eastern Time and conclude by 12:30 p.m. Eastern Time. Source
- 2026-09-30: Adjusted revenues is used by the Company’s management because it facilitates analysis of trends in underlying revenue, defined as total revenues excluding special items and the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment us Source
- 2026-09-30: Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. Source
- 2026-09-30: Changes in percentages may be expressed in basis points. Source
- 2026-09-30: The Company’s outlook excludes the potential effects of any business combinations that may occur after the date of this Report. Source
- 2026-09-30: The share repurchase program may be affected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. Source
- 2026-09-30: The program may be suspended or discontinued at any time. Source
- 2026-10-09: Donna F. Zarcone informed the Board of Directors of The Cigna Group that she will retire from the Board effective December 31, 2026. Source
- 2026-10-09: Donna F. Zarcone's retirement is not the result of any disagreement with the Company. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Increasing 2026 outlook for adjusted income from operations to at least $30.60 per share.
Said November 5, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
The Cigna Group's outlook for full year 2026 consolidated adjusted income from operations is at least $30.60 per share.
Said November 5, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
The Company plans to exit the Individual and Family Plans medical business as of January 1, 2027.
Said November 5, 2026 · Period named: January 1, 2027 · Source · Our article
Not yet checked against later reports.
The company's outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends.
Said November 5, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
Company officials expect to reaffirm consolidated adjusted earnings per share of at least $30.45 for full year 2026.
Said September 30, 2026 · Period named: full year 2026 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 12, 2026) · Later article
Company officials expect to reaffirm Evernorth Health Services adjusted income from operations of at least $6.9 billion for full year 2026.
Said September 30, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Show all (12)
The Cigna Group provides 2026 – 2030 financial targets: 10-14% Adjusted EPS CAGR; ~$50 billion in cumulative operating cash flow
Said September 30, 2026 · Period named: 2026 – 2030 · Source · Our article
Not yet checked against later reports.
Company officials expect to provide a long-term average annual adjusted EPS growth target of 10-14%.
Said September 30, 2026 · Source · Our article
Not yet checked against later reports.
Company officials expect to reaffirm consolidated adjusted revenues of approximately $280 billion for full year 2026.
Said September 30, 2026 · Period named: full year 2026 · Source · Our article
AI assessment, provisional no new evidence in later reports yet (as of November 12, 2026) · Later article
The Cigna Group’s outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends.
Said September 30, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
Company officials expect to reaffirm Cigna Healthcare medical care ratio of 83.7% to 84.7% for full year 2026.
Said September 30, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
Company officials expect to reaffirm Cigna Healthcare adjusted income from operations of at least $4.55 billion for full year 2026.
Said September 30, 2026 · Period named: full year 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| October 9, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 24,113,368 | $6,554,736,821 | +2.9% | Q3 2026 |
| State Street | 12,959,550 | $3,522,794,477 | +2.2% | Q3 2026 |
| Fidelity (FMR) | 6,813,015 | $1,851,982,015 | -15.0% | Q3 2026 |
| Geode Capital Management | 6,817,241 | $1,845,423,071 | +8.8% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 3,562,699 | $982,164,860 | — | Q2 2026 |
| Two Sigma Investments | 1,291,082 | $350,954,820 | -28.8% | Q3 2026 |
| D. E. Shaw & Co. | 1,073,592 | $291,834,513 | +283.2% | Q3 2026 |
| Citadel Advisors | 638,382 | $173,531,379 | +98.6% | Q3 2026 |
| Renaissance Technologies | 330,819 | $89,926,529 | -4.2% | Q3 2026 |
| Capital Research Global Investors | 150,511 | $40,913,450 | -87.8% | Q3 2026 |
| Bridgewater Associates | 105,182 | $28,591,623 | +19.7% | Q3 2026 |
| Millennium Management | 40,573 | $11,028,959 | -91.1% | Q3 2026 |
| T. Rowe Price | 1,244,690 | $338,345 | -1.6% | Q3 2026 |
| Wellington Management | 863 | $234,590 | -98.6% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.